Abstract:Objectives: Hypoxia is associated with human non-small cell lung cancers (NSCLC), which are highly resistant to chemotherapy. The hypoxia inducible factor (HIF) as a transcription factor in response to hypoxia indicates that it could be a novel, tumor-specific target for anticancer therapy. We hypothesized that disruption of HIF pathway through lentiviral vector-mediated HIF-1 alpha RNA interference (RNAi) could reverse the hypoxia-induced resistance to chemotherapy. Methods: We transfected Human NSCLC cell lines, SPCA1 and A549 with HIF-1 alpha specific RNAi lentiviral vectors as well as controls. HIF-1 alpha silenced cells [SPCA1/HIF-1 alpha(-) and A549/HIF-1 alpha(-)] were screened by blasticidin. They were incubated in 19 or 0.5% O-2 for 16 h followed by the assessment of chemosensitivity to cisplatin and doxorubicin with MTT and clonogenic assays. Quantitative RT-PCR and Western blot analysis were used to detect the expressions of HIF-1 alpha mRNA and protein, respectively. Moreover, flow cytometry was used to monitor the expression of P-glycoprotein. Results: Exposure of SPCA1 and A549 cells to 0.5% O-2 significantly increased resistance to cisplatin and doxorubicin, in contrast to cells incubated in normoxia. Transduction of SPCA1 with HIF-1 alpha RNAi vector resulted in sequence specific silencing with 87.2 and 84.6% decreases of HIF-1 alpha mRNA transcription and 97.3 and 94.8% of protein expressions in normoxia and hypoxia, respectively. Correspondingly, they are 89.2, 89.9% and 97.2, 88.4% decreases in A549 cells. Hypoxia-induced resistance to cisplatin and doxorubicin were reversed in SPCA1/HIF-1 alpha(-) and A549/HIF-1 alpha(-) cells. There was no significant P-glycoprotein increase induced by hypoxia in NSCLC cells. Conclusions: Our studies demonstrated that hypoxia-induced chemoresistance to cisplatin and doxorubicin in NSCLC cells is through the HIF pathway. MDR1 regulation may not be involved in hypoxia-induced chemoresistance. Combining delivery of HIF-1 alpha RNAi lentiviral vector with cisplatin-related chemotherapy regimens may enable us to develop more effective strategy for NSCLC therapy.

Oroxylin A reverses hypoxia-induced cisplatin resistance through inhibiting HIF-1α mediated XPC transcription

The Impact of Hypoxia Improvement on Laryngeal Squamous Cell Carcinoma Chemotherapy

The Role of Nrf2 and Apoptotic Signaling Pathways in Oroxylin A-Mediated Responses in Hct-116 Colorectal Adenocarcinoma Cells and Xenograft Tumors

Oroxylin A reverses P-glycoprotein-mediated multidrug resistance of MCF7/ADR cells by G2/M arrest

Oroxylin A Sensitizes Non-Small Cell Lung Cancer Cells to Anoikis Via Glucose-Deprivation-like Mechanisms: C-Src and Hexokinase II.

Oroxylin A inhibits hypoxia-induced invasion and migration of MCF-7 cells by suppressing the Notch pathway.

Targeting HDAC/OAZ1 Axis with a Novel Inhibitor Effectively Reverses Cisplatin Resistance in Non-Small Cell Lung Cancer

Oroxylin a Reverses Multi‐drug Resistance of Human Hepatoma BEL7402/5‐FU Cells Via Downregulation of P‐glycoprotein Expression by Inhibiting NF‐κB Signaling Pathway

Oroxylin a promoted apoptotic extracellular vesicles transfer of glycolytic kinases to remodel immune microenvironment in hepatocellular carcinoma model

Luteolin Sensitizes Two Oxaliplatin-Resistant Colorectal Cancer Cell Lines to Chemotherapeutic Drugs Via Inhibition of the Nrf2 Pathway

The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer

Oroxylin A Increases the Sensitivity of Temozolomide on Glioma Cells by Hypoxia‐inducible Factor 1α/hedgehog Pathway under Hypoxia

Oroxylin A promotes cancer cell-to-macrophage communication and improves immunotherapy in hepatocellular carcinoma model

Oroxylin A Suppresses the Development and Growth of Colorectal Cancer Through Reprogram of HIF1α-modulated Fatty Acid Metabolism.

Oroxylin A induces dissociation of hexokinase II from the mitochondria and inhibits glycolysis by SIRT3-mediated deacetylation of cyclophilin D in breast carcinoma.

Oroxylin A inhibits the migration of hepatocellular carcinoma cells by inducing NAG-1 expression

Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1α gene

Hypoxia-Induced Resistance To Cisplatin And Doxorubicin In Non-Small Cell Lung Cancer Is Inhibited By Silencing Of Hif-1 Alpha Gene

Oroxylin A Reverses CAM-DR of HepG2 Cells by Suppressing Integrinβ1 and Its Related Pathway.

Oroxylin A suppressed colorectal cancer metastasis by inhibiting the activation of the TGF-β/SMAD signal pathway

Oroxylin a Could Be a Promising Radiosensitizer for Esophageal Squamous Cell Carcinoma by Inducing G2/M Arrest and Activating Apoptosis